A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2016
Price : $35 *
At a glance
- Drugs QBM 076 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2016 No of arms changed from 10 to 6 as per ClinicalTrials.gov record.
- 29 Sep 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.